Anti-Henipavirus (Clone: HENV-270) – Purified No Carrier Protein

Isolated from circulating B cells of an individual exposed to equine HeV vaccine⁵.

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.

Standard Overnight on Blue Ice.

ELISA

Clone HENV-270 recognizes the C-terminus of the RBP stalk domain.

Henipavirus spp. are enveloped, single-stranded RNA viruses in the family Paramyxovirus¹. Five species have been identified, two of which, Hendra virus (HeV) and Nipah virus (NiV), are highly virulent emerging pathogens with high case-fatality ratios. The other three species, Cedar virus, Ghanaian bat virus, and Mojiang virus are not known to cause human disease. Pteropid bats are the reservoir host. HeV is transmitted by direct contact with infected horses, their fluids, or tissues¹. Horses are infected by exposure to pteropid bats. NiV is transmitted by contact with infected pigs or bats and person-to-person. Both HeV and NiV cause severe influenza-like illness that can progress to encephalitis.

Henipavirus RBP is an envelope glycoprotein.

This antibody has been tested in lateral flow assays. The best matched pair is HENV-270 (Capture)/HENV-117 (Detection).

1. Shoemaker T, Choi MJ. Chapter 4: Travel-Related Infectious Diseases, Henipaviruses. In: Brunette GW, Nemhauser JB, eds. 2020 CDC Yellow Book. CDC; National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Global Migration and Quarantine (DGMQ), Link Text
2. Aguilar HC, Ataman ZA, Aspericueta V, et al. J Biol Chem. 284(3):1628-1635. 2009.
3. Mire CE, Chan YP, Borisevich V, et al. J Infect Dis. 221(Suppl 4):S471-S479. 2020.
4. Zhu Z, Dimitrov AS, Bossart KN, et al. J Virol. 80(2):891-899. 2006.
5. Wang L-F, Harcourt BH, Yu M. Microbes Infect. 3(4):279–287. 2001.
6. Bonaparte MI, Dimitrov AS, Bossart KN. Proc Natl Acad Sci USA. 102(30):10652–10657. 2005.
7. Negrete OA, Levroney EL, Aguilar HC. Nature. 436(7049):401–405. 2005.
8. Doyle MP, Kose N, Borisevich V, et al. Cell Rep. Aug 31;36(9):109628. 2021.